Conference Perspectives

View all perspectives
      #EULAR2024 OP0149 When the Doctor says YES but the patients say NO. Data from UK BILAG-BR in moderate to severe #lupus s

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months 2 weeks ago
      #EULAR2024 OP0149 When the Doctor says YES but the patients say NO. Data from UK BILAG-BR in moderate to severe #lupus showed ~half patients who met clinical response did not improve their psychological wellbeing. Factors of discordant: ancestry, damage, SLEDAI-2K @RheumNow https://t.co/9cqcPripA2
      #EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts wi

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months 2 weeks ago
      #EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare @RheumNow https://t.co/8IIgPuZUrF
      #EULAR2024 OP0187 Can we identify a subgroup of #lupus patients at the outset who may benefit from early intensive thera

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months 2 weeks ago
      #EULAR2024 OP0187 Can we identify a subgroup of #lupus patients at the outset who may benefit from early intensive therapies inc biologics? Data from an inception cohort showed low complement & cSLEDAI=>9 were assoc w increased risk of intensive therapy need/Tx failure @RheumNow https://t.co/jmahjcqom3
      New targets and new treatments in #Sjogren’s disease:
      Long term outcomes of repeat cycles of RTX
      #EULAR2024
      CB https

      Annals of the Rheumatic Diseases ARD_BMJ

      3 months 2 weeks ago
      New targets and new treatments in #Sjogren’s disease: Long term outcomes of repeat cycles of RTX #EULAR2024 CB https://t.co/6fL3e33i8N
      STAR responder may be the way to go! Less placebo effect than CREST.
      Better in patients with low systemic activity. htt

      Bella Mehta bella_mehta

      3 months 2 weeks ago
      STAR responder may be the way to go! Less placebo effect than CREST. Better in patients with low systemic activity. https://t.co/mMYOKfG2gS
      A fantastic tool LupusGPT by @LupusEurope for our patients to help self-manage #SLE was launched yesterday. Building on

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months 2 weeks ago
      A fantastic tool LupusGPT by @LupusEurope for our patients to help self-manage #SLE was launched yesterday. Building on information from Lupus100 & supplemented by scientific data and relevant guidelines. I have tried it and worked well. Please disseminate https://t.co/a1qXGZyRE6 https://t.co/LTQM6A8Zq3
      New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compare

      Annals of the Rheumatic Diseases ARD_BMJ

      3 months 2 weeks ago
      New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated. Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA IH https://t.co/RvcONHCLvz
      Today, on National Career Nursing Assistants Day, we celebrate the nursing assistants who enhance the lives of our famil

      Rheumatology Nurses RNSociety

      3 months 2 weeks ago
      Today, on National Career Nursing Assistants Day, we celebrate the nursing assistants who enhance the lives of our families and loved ones every day! Take a moment to express your gratitude for their care and hard work. #CareerNurseAssistantsDay https://t.co/Mijr820gnE
      40% women above 60yo have #osteoarthritis. 25% have hand OA #EULAR24 https://t.co/9ZaQYIYIxn

      Vasco C Romao romaovc

      3 months 2 weeks ago
      40% women above 60yo have #osteoarthritis. 25% have hand OA #EULAR24 https://t.co/9ZaQYIYIxn
      predict secukinumab response but left out half of patient population ? selection bias @rheumnow #EULAR2024 https://t.co/

      Peter Nash drpnash

      3 months 2 weeks ago
      predict secukinumab response but left out half of patient population ? selection bias @rheumnow #EULAR2024 https://t.co/K4J6eQV0zh
      #EULAR2024

      21-24% of #APS patients have #metabolic syndrome

      Also ⬆️ rates if atherosclerotic plaque progression

      Dr Gurdeep S Dulay gurdeep_dulay

      3 months 2 weeks ago
      #EULAR2024 21-24% of #APS patients have #metabolic syndrome Also ⬆️ rates if atherosclerotic plaque progression in pts with #AntiPhospholipidSyndrome #CVD #IHD #ASCVD By @MariaTektonidou https://t.co/EZsxJE7YJa
      Fantastic presentation from @MiaRodziewicz using BILAG-BR data:

      ⭐️NPSLE had higher damage / disease activity
      ⭐?

      Sarah Dyball sarahdyball1

      3 months 2 weeks ago
      Fantastic presentation from @MiaRodziewicz using BILAG-BR data: ⭐️NPSLE had higher damage / disease activity ⭐️ NPSLE more likely to have APS ab ⭐️ RTX appears effective in NPSLE (no trials) https://t.co/25984cORj0
      Great results presented at #EULAR24 by Greg Dresler on CD19/BCMA CAR T-cell therapy. 18 additional SLE patients with gre

      Anne Troldborg TroldborgAnne

      3 months 2 weeks ago
      Great results presented at #EULAR24 by Greg Dresler on CD19/BCMA CAR T-cell therapy. 18 additional SLE patients with great response. ⁦@LUPUSDK⁩ ⁦@LupusEurope⁩ https://t.co/2C64ECzq83
      Another excellent oral presentation from UPMC myositis center by Shiri Keret at #EULAR2024. She showed that many myositi

      Rohit Aggarwal docrota

      3 months 2 weeks ago
      Another excellent oral presentation from UPMC myositis center by Shiri Keret at #EULAR2024. She showed that many myositis patient may have normal CK despite muscle weakness. However, CK is associated with outcomes over time even in patients with normal or near normal CK,… https://t.co/nAoUo8fcXh https://t.co/J8iZG4eESP
      ✅ Updated pipeline of phase 2 & 3 trials in #Lupus ⬇️ #EULAR2024
      Please let me know if something is missing or

      Laurent ARNAUD Lupusreference

      3 months 2 weeks ago
      ✅ Updated pipeline of phase 2 & 3 trials in #Lupus ⬇️ #EULAR2024 Please let me know if something is missing or incorrect 👍 https://t.co/ruuKYmAvYj

      Podcasts

      • Which One Is The Loneliest Number (9.27.2024)
      • I Cant Treat Ugly (9.20.2024)
      • Systemic Sclerosis Insights (9.13.2024)

      Catch up on Conference Podcasts

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.